ADX-246 / Aldeyra - LARVOL DELTA

Reactive Aldehyde Species Inhibitor ADX-246 Attenuates Autoantigen Expression and Tissue Fibrosis in a Pre-Clinical Model of Rheumatoid Arthritis-Associated Interstitial Lung Disease (ACR Convergence 2026) - "For the first time, these results demonstrate that an agent targeting reactive aldehydes and preventing MAA formation in lung tissues, could serve as a novel therapeutic approach in the treatment of RA-ILD. Additional research will be needed to assess the impact of RASPi (including alternative formulations) on arthritis severity, identifying any off-target effects, as well as optimal dosing and timing of treatment."

Preclinical • Fibrosis • Immunology • Inflammatory Arthritis • Interstitial Lung Disease • Pulmonary Disease • Respiratory Diseases • Rheumatoid Arthritis • Rheumatology

Aldeyra Therapeutics Highlights Recent Preclinical Data in Obesity, Atopic Dermatitis, Pain, and Alcoholic Hepatitis, and Announces Planned Pivotal Clinical Trial in Retinitis Pigmentosa, at 2024 Research & Development Day (Businesswire) - "Aldeyra will present new preclinical data from investigational RASP modulators in animal models for obesity, atopic dermatitis, inflammatory pain, and alcoholic hepatitis. In the diet-induced model of obesity, ADX-629 decreased weight and fat mass alone and in combination with a GLP-1 agonist. In the oxazolone model of atopic dermatitis, RASP modulators ADX-629, ADX-246, and ADX-248 demonstrated activity in reducing skin thickness and erosion, and in reducing spleen to body weight ratio. In the carrageenan model of inflammatory pain, ADX-246 increased tolerance to mechanical and thermal pain, and decreased joint swelling. Consistent with previously released data from ADX-629 in a model of alcoholic hepatitis, ADX-246 reduced levels of fibrosis and fat in liver."

Preclinical • Atopic Dermatitis • Immunology